The PROMISE Pediatric Study 6 to 11 Years Old

A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Pediatric 6 to 11 Years Old Study)

This is a prospective, multi-center observational study. The study is designed to measure the clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination therapy in children (6-11 years of old) with one or more copies of the F508del mutation, study the effects of ETI across a number of CF disease manifestations, and collect specimens for future research. Subjects in the study will have one "before ETI" visit within 30 days before initiation of the therapy and five "after ETI" visits over a 24-month follow-up period. Participants who have participated in the original PROMISE Pediatric Sub-Study have the option of participating in a long-term extension with annual visits performed at the 36- and 48-month timepoints. The durability of the clinical and biological changes in the PROMISE Pediatric Sub-Study can be assessed with extended follow-up, which would enable the sub-studies to consider potential clinical consequences of the biological or physiological effects being studied. This work will help to inform long term prognosis and feasibility of certain clinical trials outcomes for interventional studies and may be useful when considering research priorities in drug development. The duration of participation for each subject is 24 months (with an additional 24 months if participants agree to the optional long-term extension). NOTE: FDA has granted approval for elexacaftor, tezacaftor and ivacaftor in the 6-11 age group.

Study Overview

• Status: Active, not recruiting
• Conditions: Cystic Fibrosis; Cystic Fibrosis in Children

Detailed Description

While nearly 2000 mutations have been described, the most common disease causing CFTR mutation is F508del, which is found in >85% of patients followed in the US CF Patient Registry. Two CFTR corrector drugs (elexacaftor and tezacaftor) plus the potentiator ivacaftor have been developed and approved as a triple combination therapy for CF patients (12 years old and above) with one or two copies of the F508del mutation. We predict that over 90% of pediatric CF patients (age 6-11 y/o) will be eligible for highly effective CFTR modulator therapy in the U.S.

The PROMISE Pediatric Study is designed to measure the direct and indirect CFTR dependent anion secretion by collecting and analyzing clinical research outcomes and biomarkers on pediatric patients both before and after they begin treatment with ETI. This study will investigate the impact of ETI across a wide range of CF disease manifestations and organ systems. While specific biomarkers of special interest have been selected for detailed analysis in this study, an additional important goal is to collect blood, urine, stool, and airway epithelial cell specimens for long-term storage in a biorepository to enable future research. These samples can be made available for research beyond the current scope of work. The PROMISE Pediatric Study will provide a coordinated collection of clinical research outcomes data that can be linked with these specimens.

• Study Type: Observational
• Enrollment (Estimated): 180

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • University of Alabama at Birmingham
  • California
    • Palo Alto, California, United States, 94304
      • Stanford University Medical Center
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Children's Hospital Colorado
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Ann & Robert H. Lurie Children's Hospital of Chicago
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Riley Hospital for Children
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • John Hopkins University
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Boston Children's Hospital, Brigham & Women's Hospital
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • The Minnesota Cystic Fibrosis Center
  • Missouri
    • Kansas City, Missouri, United States, 64108
      • Children's Mercy Kansas City
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • University of North Carolina at Chapel Hill
  • Ohio
    • Cincinnati, Ohio, United States, 45229
      • Cincinnati Children's Hospital Medical Center
    • Cleveland, Ohio, United States, 44146
      • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
  • Oregon
    • Portland, Oregon, United States, 97239
      • Oregon Health Sciences University
  • Texas
    • Houston, Texas, United States, 77030
      • Baylor College of Medicine
  • Virginia
    • Richmond, Virginia, United States, 23219
      • Virginia Commonwealth University
  • Washington
    • Seattle, Washington, United States, 98105
      • Seattle Children's Hospital
  • Wisconsin
    • Madison, Wisconsin, United States, 53792
      • University of Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Children's Hospital of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 years to 9 years (Child)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Cystic Fibrosis, 6-11 years old prescribed ETI.

Description

Inclusion Criteria:

1. Written parental informed consent and assent obtained from subject and the subject's legal guardian.
2. Be willing and able to adhere to the study visit schedule and other protocol requirements.
3. All genders 6-11 years old on Day 1.
4. Diagnosis of CF.
5. CFTR mutations consistent with the FDA labeled indication for the ETI.
6. Physician intent to prescribe the ETI.
7. Able to attempt the testing and procedures required for this study, as judged by the investigator.
8. Enrolled in the Cystic Fibrosis Foundation Patient Registry.
9. Clinically stable with no significant changes in health status within the 14 days prior to Visit 1 (and inclusive of Visit 1).

Exclusion Criteria:

1. Has any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
2. Use of any ETI within the 180 days prior to Visit 1.
3. Any acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids within the 14 days prior to Visit 1 (inclusive of Visit 1) for lower respiratory tract symptoms.
4. Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, inhaled tobramycin, Cayston®, Kalydeco, Orkambi®, Symdeko®) within the 4 weeks prior to Visit 1 (inclusive of Visit 1).
5. Use of an investigational agent within the 28 days prior to Visit 1.
6. Use of chronic oral corticosteroids (equivalent to 10 mg. or more per day of prednisone) within the 28 days prior to Visit 1.
7. Treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two antibiotics (oral, IV, and/or inhaled) within the 28 days prior to Visit 1.
8. History of lung or liver transplantation,or listing for organ transplantation.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Pediatric; Cystic Fibrosis pediatric patients (6-11 years old) prescribed ETI CFTR modulator Therapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sweat Chloride at 6 months	Change in sweat chloride from Baseline to 6 months.	6 months
Sweat Chloride at 24 months	Change sweat chloride from Baseline to 24 months.	24 months
Forced expiratory volume at one second (FEV1) at 6 months	Change in FEV1 from Baseline to 6 months.	6 months
Forced expiratory volume at one second (FEV1) at 24 months	Change in FEV1 from Baseline to 24 months.	24 months
Lung Clearance Index (LCI) at 6 months	Change Lung Clearance Index (LCI) from baseline to 6 months.	6 months
Lung Clearance Index (LCI) at 24 months	Change Lung Clearance Index (LCI) from baseline to 24 months.	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Weight at 6 Months	Change in weight from Baseline to 6 months.	6 months
Weight at 24 Months	Change in weight from Baseline to 24 months.	24 months
BMI at 6 Months	Change in BMI from Baseline to 6 months.	6 months
BMI at 24 Months	Change in BMI from Baseline to 24 months.	24 months
Cystic Fibrosis Questionnaire Revised (CFQ-R) at 6 Months	Change in CFQ-R (respiratory domain) from Baseline to 6 months.	6 months
Cystic Fibrosis Questionnaire Revised (CFQ-R) at 24 Months	Change in CFQ-R (respiratory domain) from Baseline to 24 months.	24 months

Collaborators and Investigators

• Sponsor: Nicole Hamblett
• Collaborators: Cystic Fibrosis Foundation
• Investigators: Principal Investigator: Steven Rowe, MD, University of Alabama at Birmingham; Principal Investigator: David Nichols, MD, University of Washington

Study record dates

Study Major Dates

• Study Start (Actual): June 11, 2021
• Primary Completion (Estimated): December 19, 2025
• Study Completion (Estimated): December 19, 2025

Study Registration Dates

• First Submitted: October 27, 2020
• First Submitted That Met QC Criteria: October 27, 2020
• First Posted (Actual): November 3, 2020

Study Record Updates

• Last Update Posted (Actual): December 26, 2023
• Last Update Submitted That Met QC Criteria: December 22, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: Pediatric; Cystic Fibrosis; CF; Trikafta; CFTR Modulator; Triple Combination Therapy; ETI; elexacaftor/texacaftor/ivacaftor
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Pancreatic Diseases; Fibrosis; Cystic Fibrosis
• Other Study ID Numbers: PROMISE-OB-18 Pediatric Study

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No